A Phase 2 interventional study of Travoprost Intracameral Implant exchanged at Month 12 and Travoprost Intracameral Implant exchanged at Month 3 in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Glaukos Corporation. Completed at 1 site in Armenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Glaukos Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 12th largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2021, is one of 6 in phase 2, and was the 44th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Jonathon Myers · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 135 across the 45 interventional studies. Of the 43 that completed or were terminated, 23 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 46 have an industry lead sponsor. The 10 most frequent:
Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
43 studies in Glaucoma, Open-Angle by Glaukos Corporation: 7 open now, 10 under way, 2 of them phase 3. Of 30 finished, 8 (27%) have results posted.
Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, this one is the 10th largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 38th registered.
Glaukos Corporation’s Glaucoma, Open-Angle studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Glaukos Corporation’s 43 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the performance of the Travoprost Intracameral Implant by determining residual drug in explanted implants of the Travoprost Intracameral Implant and by determining aqueous humor concentrations of travoprost free acid at specified timepoints post administration through 24 months
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Travoprost Intracameral Implant Exchanged at Month 12
Drug: Travoprost Intracameral Implant exchanged at Month 12
Travoprost Intracameral Implant Exchanged at Month 3
Drug: Travoprost Intracameral Implant exchanged at Month 3
Travoprost Intracameral Implant Exchanged at Month 6
Drug: Travoprost Intracameral Implant exchanged at Month 6
Travoprost Intracameral Implant Exchanged at Month 24
Drug: Travoprost Intracameral Implant exchanged at Month 24
Travoprost Intracameral Implant Exchanged at Month 21
Drug: Travoprost intracameral implant exchanged at Month 21
Travoprost Intracameral Implant Exchanged at Month 18
Drug: Travoprost intracameral implant exchanged at Month 18
Travoprost Intracameral Implant Exchanged at Month 15
Drug: Travoprost intracameral implant exchanged at Month 15
intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12
Also known as: iDose TR
intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3
Also known as: iDose TR
intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6
Also known as: iDose TR
intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24
Also known as: iDose TR
intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21
Also known as: iDose TR
intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18
Also known as: iDose TR
intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15
Also known as: iDose TR
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration
concentration of travoprost free acid (ng/mL) in the aqueous humor 12 months post-administration as assessed by liquid chromatography tandem mass spectrometry (LC-MS/MS)
Time frame: month 12
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 3 Months Post-administration
concentration of travoprost free acid (ng/mL) in the aqueous humor 3 months post-administration as assessed by LC-MS/MS
Time frame: month 3
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 6 Months Post-administration
concentration of travoprost free acid (ng/mL) in the aqueous humor 6 months post-administration as assessed by LC-MS/MS
Time frame: month 6
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 24 Months Post-administration
concentration of travoprost free acid (ng/mL) in the aqueous humor 24 months post-administration as assessed by LC-MS/MS
Time frame: month 24
Travoprost Free Acid Concentration(ng/mL) in Aqueous Humor 21 Months Post-administration
concentration of travoprost free acid (ng/mL) in the aqueous humor 21 months post-administration as assessed by LC-MS/MS
Time frame: month 21
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 18 Months Post-administration
concentration of travoprost free acid (ng/mL) in the aqueous humor 18 months post-administration as assessed by LC-MS/MS
Time frame: month 18
Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 15 Months Post-administration
concentration of travoprost free acid (ng/mL) in the aqueous humor 15 months post-administration as assessed by LC-MS/MS
Time frame: month 15
Percent Residual Travoprost in Explanted Implant 12 Months Post-administration
percent of travoprost compared to baseline in explanted implant 12 months post-administration as assessed by high performance liquid chromatography (HPLC)
Time frame: month 12
Percent Residual Travoprost in Explanted Implant 3 Months Post-administration
percent of travoprost compared to baseline in explanted implant 3 months post-administration as assessed by HPLC
Time frame: month 3
Percent Residual Travoprost in Explanted Implant 6 Months Post-administration
percent of travoprost compared to baseline in explanted implant 6 months post-administration as assessed by HPLC
Time frame: month 6
Percent Residual Travoprost in Explanted Implant 24 Months Post-administration
percent of travoprost compared to baseline in explanted implant 24 months post-administration as assessed by HPLC
Time frame: month 24
Percent Residual Travoprost in Explanted Implant 21 Months Post-administration
percent of travoprost compared to baseline in explanted implant 21 months post-administration as assessed by HPLC
Time frame: month 21
Percent Residual Travoprost in Explanted Implant 18 Months Post-administration
percent of travoprost compared to baseline in explanted implant 18 months post-administration as assessed by HPLC
Time frame: month 18
Percent Residual Travoprost in Explanted Implant 15 Months Post-administration
percent of travoprost compared to baseline in explanted implant 15 months post-administration as assessed by HPLC
Time frame: month 15
| Milestone | Cohort 1 (12-month Exchange) | Cohort 2 (3-month Exchange) | Cohort 3 (6-month Exchange) | Cohort 4 (24-month Exchange) | Cohort 5 (21-month Exchange) | Cohort 6 (18-month Exchange) | Cohort 7 (15-month Exchange) |
|---|---|---|---|---|---|---|---|
| Started | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
| Completed | 29 | 29 | 28 | 27 | 25 | 29 | 28 |
| Not completed | 1 | 1 | 2 | 3 | 5 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 3 | 1 | 2 |
| Withdrew: Moved away | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Cohort 1 (12-month Exchange) | Cohort 2 (3-month Exchange) | Cohort 3 (6-month Exchange) | Cohort 4 (24-month Exchange) | Cohort 5 (21-month Exchange) | Cohort 6 (18-month Exchange) | Cohort 7 (15-month Exchange) |
|---|---|---|---|---|---|---|---|
| Started | 29 | 29 | 28 | 27 | 25 | 29 | 28 |
| Completed | 29 | 29 | 28 | 27 | 25 | 29 | 28 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
concentration of travoprost free acid (ng/mL) in the aqueous humor 12 months post-administration as assessed by liquid chromatography tandem mass spectrometry (LC-MS/MS)
| ng/mL | Cohort 1 (12-month Exchange) |
|---|---|
| Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration | 5.57 ± 3.02 |
concentration of travoprost free acid (ng/mL) in the aqueous humor 3 months post-administration as assessed by LC-MS/MS
| ng/mL | Cohort 2 (3-month Exchange) |
|---|---|
| Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 3 Months Post-administration | 4.98 ± 2.50 |
concentration of travoprost free acid (ng/mL) in the aqueous humor 6 months post-administration as assessed by LC-MS/MS
| ng/mL | Cohort 3 (6-month Exchange) |
|---|---|
| Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 6 Months Post-administration | 3.74 ± 2.22 |
concentration of travoprost free acid (ng/mL) in the aqueous humor 24 months post-administration as assessed by LC-MS/MS
| ng/mL | Cohort 4 (24-month Exchange) |
|---|---|
| Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 24 Months Post-administration | 3.35 ± 1.51 |
concentration of travoprost free acid (ng/mL) in the aqueous humor 21 months post-administration as assessed by LC-MS/MS
| ng/mL | Cohort 5 (21-month Exchange) |
|---|---|
| Travoprost Free Acid Concentration(ng/mL) in Aqueous Humor 21 Months Post-administration | 3.80 ± 1.58 |
concentration of travoprost free acid (ng/mL) in the aqueous humor 18 months post-administration as assessed by LC-MS/MS
| ng/mL | Cohort 6 (18-month Exchange) |
|---|---|
| Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 18 Months Post-administration | 2.22 ± 1.24 |
concentration of travoprost free acid (ng/mL) in the aqueous humor 15 months post-administration as assessed by LC-MS/MS
| ng/mL | Cohort 7 15-month Exchange) |
|---|---|
| Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 15 Months Post-administration | 2.03 ± 0.736 |
percent of travoprost compared to baseline in explanted implant 12 months post-administration as assessed by high performance liquid chromatography (HPLC)
| percentage of initial | Cohort 1 (12-month Exchange) |
|---|---|
| Percent Residual Travoprost in Explanted Implant 12 Months Post-administration | 50.2 ± 6.58 |
percent of travoprost compared to baseline in explanted implant 3 months post-administration as assessed by HPLC
| percentage of initial | Cohort 2 (3-month Exchange) |
|---|---|
| Percent Residual Travoprost in Explanted Implant 3 Months Post-administration | 78.8 ± 3.15 |
percent of travoprost compared to baseline in explanted implant 6 months post-administration as assessed by HPLC
| percentage of initial | Cohort 3 (6-month Exchange) |
|---|---|
| Percent Residual Travoprost in Explanted Implant 6 Months Post-administration | 69.8 ± 8.51 |
percent of travoprost compared to baseline in explanted implant 24 months post-administration as assessed by HPLC
| percentage of initial | Cohort 4 (24-month Exchange) |
|---|---|
| Percent Residual Travoprost in Explanted Implant 24 Months Post-administration | 16.3 ± 7.88 |
percent of travoprost compared to baseline in explanted implant 21 months post-administration as assessed by HPLC
| percentage of initial | Cohort 5 (21-month Exchange) |
|---|---|
| Percent Residual Travoprost in Explanted Implant 21 Months Post-administration | 28.0 ± 5.76 |
percent of travoprost compared to baseline in explanted implant 18 months post-administration as assessed by HPLC
| percentage of initial | Cohort 6 (18-month Exchange) |
|---|---|
| Percent Residual Travoprost in Explanted Implant 18 Months Post-administration | 34.8 ± 7.09 |
percent of travoprost compared to baseline in explanted implant 15 months post-administration as assessed by HPLC
| percentage of initial | Cohort 7 (15-month Exchange) |
|---|---|
| Percent Residual Travoprost in Explanted Implant 15 Months Post-administration | 38.6 ± 8.23 |
Collected over initial travoprost intracameral implant period plus 4 weeks post-exchange. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (12-month Exchange) | 1/30 (3.3%) | 1/30 (3.3%) | 4/30 (13.3%) |
| Cohort 2 (3-month Exchange) | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Cohort 3 (6-month Exchange) | 0/30 (0%) | 0/30 (0%) | 5/30 (16.7%) |
| Cohort 4 (24-month Exchange) | 0/30 (0%) | 0/30 (0%) | 3/30 (10%) |
| Cohort 5 (21-month Exchange) | 1/30 (3.3%) | 1/30 (3.3%) | 0/30 (0%) |
| Cohort 6 (18-month Exchange) | 0/30 (0%) | 0/30 (0%) | 1/30 (3.3%) |
| Cohort 7 (15-month Exchange) | 0/30 (0%) | 0/30 (0%) | 1/30 (3.3%) |
| Event | Cohort 1 (12-month Exchange) | Cohort 2 (3-month Exchange) | Cohort 3 (6-month Exchange) | Cohort 4 (24-month Exchange) | Cohort 5 (21-month Exchange) | Cohort 6 (18-month Exchange) | Cohort 7 (15-month Exchange) |
|---|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 1/30 | 0/30 | 0/30 | 0/30 | 1/30 | 0/30 | 0/30 |
| Event | Cohort 1 (12-month Exchange) | Cohort 2 (3-month Exchange) | Cohort 3 (6-month Exchange) | Cohort 4 (24-month Exchange) | Cohort 5 (21-month Exchange) | Cohort 6 (18-month Exchange) | Cohort 7 (15-month Exchange) |
|---|---|---|---|---|---|---|---|
| Corona virus infectionInfections and infestations | 2/30 | 0/30 | 3/30 | 0/30 | 0/30 | 0/30 | 0/30 |
| Intraocular pressure increasedInvestigations | 2/30 | 0/30 | 1/30 | 2/30 | 0/30 | 1/30 | 0/30 |
| InfluenzaInfections and infestations | 1/30 | 0/30 | 0/30 | 1/30 | 0/30 | 0/30 | 0/30 |
| PneumoniaInfections and infestations | 0/30 | 0/30 | 0/30 | 0/30 | 0/30 | 0/30 | 1/30 |
| IridodialysisEye disorders | 0/30 | 0/30 | 0/30 | 1/30 | 0/30 | 0/30 | 0/30 |
| HyphaemaInjury, poisoning and procedural complications | 0/30 | 0/30 | 1/30 | 0/30 | 0/30 | 0/30 | 0/30 |
only a single eye (defined as the study eye) was analyzed in the study
| Age, Categorical(Participants) | Cohort 1 (12-month Exchange) | Cohort 2 (3-month Exchange) | Cohort 3 (6-month Exchange) | Cohort 4 (24-month Exchange) | Cohort 5 (21-month Exchange) | Cohort 6 (18-month Exchange) | Cohort 7 (15-month Exchange) | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 17 | 14 | 14 | 16 | 14 | 16 | 12 | 103 |
| >=65 years | 13 | 16 | 16 | 14 | 16 | 14 | 18 | 107 |
| Sex: Female, Male(Participants) | Cohort 1 (12-month Exchange) | Cohort 2 (3-month Exchange) | Cohort 3 (6-month Exchange) | Cohort 4 (24-month Exchange) | Cohort 5 (21-month Exchange) | Cohort 6 (18-month Exchange) | Cohort 7 (15-month Exchange) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 15 | 16 | 14 | 15 | 10 | 17 | 16 | 103 |
| Male | 15 | 14 | 16 | 15 | 20 | 13 | 14 | 107 |
| Race (NIH/OMB)(Participants) | Cohort 1 (12-month Exchange) | Cohort 2 (3-month Exchange) | Cohort 3 (6-month Exchange) | Cohort 4 (24-month Exchange) | Cohort 5 (21-month Exchange) | Cohort 6 (18-month Exchange) | Cohort 7 (15-month Exchange) | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 210 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 1 (12-month Exchange) | Cohort 2 (3-month Exchange) | Cohort 3 (6-month Exchange) | Cohort 4 (24-month Exchange) | Cohort 5 (21-month Exchange) | Cohort 6 (18-month Exchange) | Cohort 7 (15-month Exchange) | Total |
|---|---|---|---|---|---|---|---|---|
| Armenia | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 210 |
| Type of Disease(Participants) | Cohort 1 (12-month Exchange) | Cohort 2 (3-month Exchange) | Cohort 3 (6-month Exchange) | Cohort 4 (24-month Exchange) | Cohort 5 (21-month Exchange) | Cohort 6 (18-month Exchange) | Cohort 7 (15-month Exchange) | Total |
|---|---|---|---|---|---|---|---|---|
| Open-angle glaucoma | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 210 |
| Ocular hypertension | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Nov 2023, 31 months.
Results were first posted in Oct 2024, 11 months after primary completion.
Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 31 months is above that.
Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost